Prior to his retirement, Dr John Holt focused on two radiowave therapy treatments for cancer. These 2 modalities form the basis of the comprehensive research being conducted by the Institute:
- UHF/XRT: Exposure of a patient to radiowaves acting as a radiosensitising agent prior to low-dose, external-beam radiotherapy using x or y-rays (Holt 1975).
- GMI/UHF: Injection of a compound referred to as “glycolytic metabolic inhibitors” (GMI) to disrupt the metabolism of cancer cells prior to exposure to radiowaves (Holt 1983).
Dr Holt proposed that both modalities are effective at the specific frequency of 434 MHz (megahertz) in the UHF (ultra-high frequency) band. Radiowave therapy is not a microwave treatment and nor is any therapeutic affect hyperthermic. Radiowaves is energy in the radiofrequency (RF) spectrum, the details of which is described in more detail in this section.
Dr Holt claimed he treated thousands of patients with one or other of his two radiowave therapies over a period of 30 years.
Note: the distinction between radiowave therapy using non-ionising, radiofrequency radiation and radiotherapy using x-rays or y-rays (ionizing radiation). Both terms come from the Latin, radius meaning ray.